ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of va...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Neurol
Huvudupphovsmän: Lingor, Paul, Weber, Markus, Camu, William, Friede, Tim, Hilgers, Reinhard, Leha, Andreas, Neuwirth, Christoph, Günther, René, Benatar, Michael, Kuzma-Kozakiewicz, Magdalena, Bidner, Helen, Blankenstein, Christiane, Frontini, Roberto, Ludolph, Albert, Koch, Jan C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2019
Ämnen:
Neurology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6446974/
https://ncbi.nlm.nih.gov/pubmed/30972018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00293
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk